Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ficlatuzumab||AV-299|SCH900105||HGF Antibody 4||Ficlatuzumab (AV-299) is a monoclonal antibody that targets HGF and inhibits c-MET/HGF signaling, potentially resulting in decreased tumor growth (PMID: 23493885, PMID: 29346833, PMID: 32545260).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Ficlatuzumab||Phase I||Actionable||In a Phase I trial, Ficlatuzumab treatment resulted in stable disease in 57% (12/21) of patients with advanced solid tumors and a decrease in phosphorylated Met in one patient with multiple myeloma (PMID: 24901237).||24901237|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03422536||Phase II||Ficlatuzumab Cetuximab + Ficlatuzumab||Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma||Recruiting|
|NCT02090127||Phase I||Ficlatuzumab||Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient||No longer available|